Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting

Kejie Zhang; Aakash Desai; Dongfeng Zeng; Tiejun Gong; Peihua Lu; Michael Wang

doi:10.18632/oncotarget.13314

Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting

Kejie Zhang, Aakash Desai, Dongfeng Zeng, Tiejun Gong, Peihua Lu, Michael Wang

Lymphoma-Myeloma

Research output: Contribution to journal › Review article › peer-review

16 Scopus citations

Abstract

Despite the availability of various anticancer agents, Multiple Myeloma (MM) remains incurable in most cases, along with high relapse rate in the patients treated with these agents. The year 2015 saw major advancements in our battle against multiple myeloma. In 2015, the U.S. Food and Drug Administration (FDA) approved three new therapies for multiple myeloma, namely Ixazomib (an oral proteasome inhibitor), Daratumumab and Elotuzumab (monoclonal antibodies against CD38 and SLAMF7 respectively). The purpose of this review is to provide a detailed analysis of these aforementioned breakthrough therapies and two other newer agents, Filanesib (kinesis spindle inhibitor) and selinexor (SINE inhibitor), presented at the 2015 annual meeting of American Society of Hematology (ASH). We also describe the role of agents targeting PD-1 axis and chimeric antigen receptor T (CAR-T) cells in the treatment of MM.

Original language	English (US)
Pages (from-to)	10748-10759
Number of pages	12
Journal	Oncotarget
Volume	8
Issue number	6
DOIs	https://doi.org/10.18632/oncotarget.13314
State	Published - 2017

Keywords

Daratumumab
Elotuzumab
Ixazomib
Multiple myeloma

ASJC Scopus subject areas

Oncology

Access to Document

10.18632/oncotarget.13314

Cite this

@article{c3d7f7d5e3094d629041481e699eb36c,

title = "Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting",

abstract = "Despite the availability of various anticancer agents, Multiple Myeloma (MM) remains incurable in most cases, along with high relapse rate in the patients treated with these agents. The year 2015 saw major advancements in our battle against multiple myeloma. In 2015, the U.S. Food and Drug Administration (FDA) approved three new therapies for multiple myeloma, namely Ixazomib (an oral proteasome inhibitor), Daratumumab and Elotuzumab (monoclonal antibodies against CD38 and SLAMF7 respectively). The purpose of this review is to provide a detailed analysis of these aforementioned breakthrough therapies and two other newer agents, Filanesib (kinesis spindle inhibitor) and selinexor (SINE inhibitor), presented at the 2015 annual meeting of American Society of Hematology (ASH). We also describe the role of agents targeting PD-1 axis and chimeric antigen receptor T (CAR-T) cells in the treatment of MM.",

keywords = "Daratumumab, Elotuzumab, Ixazomib, Multiple myeloma",

author = "Kejie Zhang and Aakash Desai and Dongfeng Zeng and Tiejun Gong and Peihua Lu and Michael Wang",

year = "2017",

doi = "10.18632/oncotarget.13314",

language = "English (US)",

volume = "8",

pages = "10748--10759",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals",

number = "6",

}

TY - JOUR

T1 - Magic year for multiple myeloma therapeutics

T2 - Key takeaways from the ASH 2015 annual meeting

AU - Zhang, Kejie

AU - Desai, Aakash

AU - Zeng, Dongfeng

AU - Gong, Tiejun

AU - Lu, Peihua

AU - Wang, Michael

PY - 2017

Y1 - 2017

N2 - Despite the availability of various anticancer agents, Multiple Myeloma (MM) remains incurable in most cases, along with high relapse rate in the patients treated with these agents. The year 2015 saw major advancements in our battle against multiple myeloma. In 2015, the U.S. Food and Drug Administration (FDA) approved three new therapies for multiple myeloma, namely Ixazomib (an oral proteasome inhibitor), Daratumumab and Elotuzumab (monoclonal antibodies against CD38 and SLAMF7 respectively). The purpose of this review is to provide a detailed analysis of these aforementioned breakthrough therapies and two other newer agents, Filanesib (kinesis spindle inhibitor) and selinexor (SINE inhibitor), presented at the 2015 annual meeting of American Society of Hematology (ASH). We also describe the role of agents targeting PD-1 axis and chimeric antigen receptor T (CAR-T) cells in the treatment of MM.

AB - Despite the availability of various anticancer agents, Multiple Myeloma (MM) remains incurable in most cases, along with high relapse rate in the patients treated with these agents. The year 2015 saw major advancements in our battle against multiple myeloma. In 2015, the U.S. Food and Drug Administration (FDA) approved three new therapies for multiple myeloma, namely Ixazomib (an oral proteasome inhibitor), Daratumumab and Elotuzumab (monoclonal antibodies against CD38 and SLAMF7 respectively). The purpose of this review is to provide a detailed analysis of these aforementioned breakthrough therapies and two other newer agents, Filanesib (kinesis spindle inhibitor) and selinexor (SINE inhibitor), presented at the 2015 annual meeting of American Society of Hematology (ASH). We also describe the role of agents targeting PD-1 axis and chimeric antigen receptor T (CAR-T) cells in the treatment of MM.

KW - Daratumumab

KW - Elotuzumab

KW - Ixazomib

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=85011955353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011955353&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.13314

DO - 10.18632/oncotarget.13314

M3 - Review article

C2 - 27863374

AN - SCOPUS:85011955353

SN - 1949-2553

VL - 8

SP - 10748

EP - 10759

JO - Oncotarget

JF - Oncotarget

IS - 6

ER -

Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this